Objectives: Compare oncologic outcomes between single-segment and multi-segment resections in patients with clinical stage IA1 and IA2 non-small cell lung cancer.
Methods: A retrospective review (2011-2022) was conducted using a prospectively maintained database. Patients undergoing anatomical segmentectomy for clinical stage IA ≤ 2 cm non-small cell lung cancers were included. Patients were grouped into single-segment and multi-segment resections. Patients were excluded if they had neuroendocrine tumors, small cell lung cancer, underwent wedge resection, or lobectomy. The primary outcome was loco-regional recurrence. Secondary outcomes of disease-free survival, loco-regional recurrence-free survival, overall survival, pathologic upstaging, and perioperative complications were evaluated.
Results: 190 (63.8%) patients had single-segment resection and 108 (36.2%) had multi-segment resection. The single-segment resection group had smaller tumors (1.3 vs 1.45 cm, p = 0.02), but no significant difference in margin length (1.7 vs 2 cm, p = 0.15). Fewer lymph nodes were resected in single-segment resection (7 vs 10, p < 0.001), and a significantly lower rate of pathologic upstaging (4.2% vs 10.2%, p = 0.03) was observed compared with multi-segment resection. Nevertheless, loco-regional recurrence developed in 6.3% of patients after single-segment resection and 7.4% patients following multi-segment resection (p = 0.72). With a median follow-up duration of 40 months, five-year disease-free survival, loco-regional recurrence-free survival, and overall survival was 73%, 89%, and 87% following single-segment resection compared to 78%, 95%, and 84% after multi-segment resection.
Conclusions: For patients with clinical stage IA non-small cell lung cancers ≤2 cm, loco-regional recurrence and survival is not different based on whether patients receive a single-segment or multi-segment resection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ejcts/ezaf082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical stage-specific prognostic impact of adequate lymphadenectomy in early-stage lung cancer.
Eur J Cardiothorac Surg
March 2025
Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, ; Taipei City, Taiwan.
Objectives: To assess the prognostic impact of adequate lymphadenectomy and determine the optimal nodal assessment for different clinical stages of lung cancer.
Methods: We retrospectively reviewed 1214 patients with clinical stage I-III non-small cell lung cancer who had preoperative PET/CT and curative surgery (2006-2017). Patients were categorized based on whether they had adequate [R0] or inadequate lymphadenectomy [R(un)].
All segments are created equal: locoregional recurrence and survival after single versus multi-segment resection in patients with clinical stage IA ≤ 2 cm non-small cell lung cancer.
Eur J Cardiothorac Surg
March 2025
Department of Cardiothoracic Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 525 E 68 St, M-404, New York, NY 10065, USA.
Objectives: Compare oncologic outcomes between single-segment and multi-segment resections in patients with clinical stage IA1 and IA2 non-small cell lung cancer.
Methods: A retrospective review (2011-2022) was conducted using a prospectively maintained database. Patients undergoing anatomical segmentectomy for clinical stage IA ≤ 2 cm non-small cell lung cancers were included.
Pilot Study of Metabolomic Biomarkers Associated with Outcomes in Patients with Lung Cancer Undergoing Radiation Therapy.
J Proteome Res
March 2025
Department of Radiation Oncology, The Ohio State University, Columbus, Ohio 43210, United States.
Lung cancer stands as the leading cause of cancer-related death worldwide, impacting both men and women in the United States and beyond. Radiation therapy (RT) serves as a key treatment modality for various lung malignancies. Our study aims to systematically assess the prognosis and influence of RT on metabolic reprogramming in patients diagnosed with nonsmall-cell lung cancer (NSCLC) through longitudinal metabolic profiling.
View Article and Find Full Text PDFA human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis.
Sci Transl Med
March 2025
Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA 92037, USA.
Interstitial lung disease (ILD) consists of a group of immune-mediated disorders that can cause inflammation and progressive fibrosis of the lungs, representing an area of unmet medical need given the lack of disease-modifying therapies and toxicities associated with current treatment options. Tissue-specific splice variants (SVs) of human aminoacyl-tRNA synthetases (aaRSs) are catalytic nulls thought to confer regulatory functions. One example from human histidyl-tRNA synthetase (HARS), termed HARS because the splicing event resulted in a protein encompassing the WHEP-TRS domain of HARS (a structurally conserved domain found in multiple aaRSs), is enriched in human lung and up-regulated by inflammatory cytokines in lung and immune cells.
View Article and Find Full Text PDFLipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.
Sci Adv
March 2025
Department of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lung cancer exhibits altered metabolism, influencing its response to radiation. To investigate the metabolic regulation of radiation response, we conducted a comprehensive, metabolic-wide CRISPR-Cas9 loss-of-function screen using radiation as selection pressure in human non-small cell lung cancer. Lipoylation emerged as a key metabolic target for radiosensitization, with lipoyltransferase 1 (LIPT1) identified as a top hit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!